Herantis Pharma Oyj (HRTIS.HE)
EUR 1.66
(0.91%)
EUR 1.66
(0.91%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 2.01 Million EUR | -67.91% |
| 2022 | 629.24 Million EUR | 6968.54% |
| 2021 | 8.9 Million EUR | 0.78% |
| 2020 | 8.83 Million EUR | -4.19% |
| 2019 | 9.21 Million EUR | 27.4% |
| 2018 | 7.23 Million EUR | -3.28% |
| 2017 | 7.48 Million EUR | -13.31% |
| 2016 | 8.63 Million EUR | 6.69% |
| 2015 | 8.08 Million EUR | 4.05% |
| 2014 | 7.77 Million EUR | 208.39% |
| 2013 | 2.52 Million EUR | 13.82% |
| 2012 | 2.21 Million EUR | 15.35% |
| 2011 | 1.92 Million EUR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 1.6 Million EUR | -20.37% |
| 2024 Q2 | 1.6 Million EUR | 0.0% |
| 2023 Q2 | 6.99 Million EUR | 0.0% |
| 2023 FY | 2.01 Million EUR | -99.68% |
| 2023 Q3 | 2.01 Million EUR | -71.14% |
| 2023 Q4 | 2.01 Million EUR | 0.0% |
| 2023 Q1 | 6.99 Million EUR | 11.18% |
| 2022 Q4 | 629.24 Million EUR | 9900.01% |
| 2022 Q3 | 6.29 Million EUR | -28.78% |
| 2022 FY | 629.24 Million EUR | 6968.54% |
| 2022 Q1 | 8.83 Million EUR | -0.76% |
| 2022 Q2 | 8.83 Million EUR | 0.01% |
| 2021 Q2 | 8.56 Million EUR | 0.01% |
| 2021 Q4 | 8.9 Million EUR | 0.0% |
| 2021 Q3 | 8.9 Million EUR | 3.96% |
| 2021 FY | 8.9 Million EUR | 0.78% |
| 2021 Q1 | 8.56 Million EUR | -3.07% |
| 2020 Q2 | 8.32 Million EUR | 0.0% |
| 2020 FY | 8.83 Million EUR | -4.19% |
| 2020 Q1 | 8.32 Million EUR | -9.65% |
| 2020 Q4 | 8.83 Million EUR | 0.0% |
| 2020 Q3 | 8.83 Million EUR | 6.04% |
| 2019 Q1 | 7.52 Million EUR | 3.92% |
| 2019 Q2 | 7.52 Million EUR | 0.0% |
| 2019 FY | 9.21 Million EUR | 27.4% |
| 2019 Q4 | 9.21 Million EUR | 0.0% |
| 2019 Q3 | 9.21 Million EUR | 22.59% |
| 2018 Q3 | 7.23 Million EUR | 1.94% |
| 2018 Q2 | 7.09 Million EUR | 0.0% |
| 2018 Q1 | 7.09 Million EUR | -5.12% |
| 2018 FY | 7.23 Million EUR | -3.28% |
| 2018 Q4 | 7.23 Million EUR | 0.0% |
| 2017 Q1 | 9.37 Million EUR | 8.58% |
| 2017 FY | 7.48 Million EUR | -13.31% |
| 2017 Q2 | 9.37 Million EUR | 0.0% |
| 2017 Q4 | 7.48 Million EUR | 0.0% |
| 2017 Q3 | 7.48 Million EUR | -20.16% |
| 2016 Q4 | 8.63 Million EUR | 0.0% |
| 2016 Q1 | 8.18 Million EUR | 1.13% |
| 2016 Q2 | 8.18 Million EUR | 0.0% |
| 2016 FY | 8.63 Million EUR | 6.69% |
| 2016 Q3 | 8.63 Million EUR | 5.5% |
| 2015 Q1 | 7.76 Million EUR | -0.13% |
| 2015 FY | 8.08 Million EUR | 4.05% |
| 2015 Q3 | 8.08 Million EUR | 4.19% |
| 2015 Q4 | 8.08 Million EUR | 0.0% |
| 2015 Q2 | 7.76 Million EUR | 0.0% |
| 2014 Q2 | 6.79 Million EUR | 211.99% |
| 2014 Q3 | 7.77 Million EUR | 14.37% |
| 2014 FY | 7.77 Million EUR | 208.39% |
| 2014 Q4 | 7.77 Million EUR | 0.0% |
| 2014 Q1 | 2.17 Million EUR | -13.58% |
| 2013 Q3 | 2.52 Million EUR | 0.0% |
| 2013 Q4 | 2.52 Million EUR | 0.0% |
| 2013 FY | 2.52 Million EUR | 13.82% |
| 2013 Q1 | 2.45 Million EUR | 0.0% |
| 2012 FY | 2.21 Million EUR | 15.35% |
| 2011 FY | 1.92 Million EUR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Biohit Oyj | 3.5 Million EUR | 42.306% |
| Nanoform Finland Oyj | 11.18 Million EUR | 81.951% |